Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRABiotechnology
-$0.10 today
- Market cap
- $69.21M
- Beta
- 2.76
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$1.24
Volume 1.50M
Average 2.02M
NMRA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $38.6M fell 26.0% year over year, behind the -21.6% change in trailing-twelve-month research & development. Sequentially, it fell 13.6% from the prior quarter. Over 3 fiscal years it compounded at +18.9% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -26.0% toward the trailing-twelve-month pace of -21.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 176.07M USD
- Year-over-year change
- -12.4%
- 4-year CAGR
- -4.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 176.07M | -12.4% |
| FY2024 | 2024-12-31 | 200.93M | +40.8% |
| FY2023 | 2023-12-31 | 142.72M | +36.2% |
| FY2022 | 2022-12-31 | 104.75M | -50.8% |
| FY2021 | 2021-12-31 | 212.78M | — |
Research & Development vs competitors
How NMRA compares with its peers on the latest reported figures
- NMRA's LTM Mar 2026 research & development of $162.51M is the 4th highest of the 10 companies compared; the peer median is $96.67M.
- Its year-over-year change of -21.6% is the 6th highest of 10, against a peer median of -15.8%.
- Over three fiscal years its annual growth of +18.9% compares with a peer median of +3.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $346.63M | -8.7% | +56.3% | 4685.4% |
| LTM Mar 2026 | $230.13M | +16.7% | +43.3% | 362.4% | |
| LTM Mar 2026 | $219.98M | +42.7% | +34.6% | 249.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
| LTM Mar 2026 | $112.11M | -27.3% | +3.1% | 121.1% | |
| LTM Mar 2026 | $96.67M | -53.8% | -0.2% | 166.8% | |
| LTM Mar 2026 | $94.95M | -15.8% | -17.7% | 119.9% | |
| LTM Mar 2026 | $70.57M | -39.3% | -10.3% | 713.3% | |
| LTM Mar 2026 | $58.28M | -31.8% | +5.0% | 83.7% | |
| LTM Mar 2026 | $56.78M | +0.2% | -9.9% | — | |
| Peer median (excluding NMRA) | $96.67M | -15.8% | +3.1% | 208.1% | |
Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 0 | 5M |
| Gross Profit | 0 | 0 | (668K) | 0 | (5M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 212.78M | 104.75M | 142.72M | 200.93M | 176.07M |
| Selling, General & Admin | 24.55M | 31.12M | 44.81M | 62.54M | 60.09M |
| Operating Expenses | 237.32M | 135.87M | 187.53M | 263.46M | 236.16M |
| Depreciation & Amortization | 538K | 594K | 668K | 631K | 208K |
| EBITDA | (236.77M) | (130.31M) | (234.99M) | (242.98M) | (233.37M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (237.32M) | (135.87M) | (188.19M) | (263.46M) | (241.16M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 4.56M | 16.61M | 19.93M | 8.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 3.22M |
| Other Income / Expenses | 11K | 4.97M | (47.46M) | 19.86M | 4.36M |
| Income Before Tax | (237.31M) | (130.9M) | (235.66M) | (243.61M) | (236.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 268K | 178K | 130K |
| Net Income | (237.31M) | (130.9M) | (235.93M) | (243.79M) | (236.93M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.56) | (0.86) | (1.49) | (1.53) | (1.45) |
| EPS (Diluted) | (1.56) | (0.86) | (1.49) | (1.53) | (1.45) |
| Weighted Avg Shares | 151.95M | 151.95M | 158.83M | 159.38M | 163.39M |
| Weighted Avg Shares (Diluted) | 151.95M | 151.95M | 158.83M | 159.38M | 163.39M |
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.